



Haem-Match

Dr Sara Trompeter
Consultant Haematologist UCLH and NHSBT
Cambridge Symposium
30 September 2024

So far, we have heard that:




Many patients with haemoglobin disorders need transfusions with very little other treatment options




Patients with sickle cell have a high incidence of new antibody formation



We are transfusing a lot of blood




There are a lot of red cell antigens




There is a new high throughput, “cheap” genetic test for extended antigen typing

What is the reality of blood matching?

- **Extended typing of donors and patients**
 - Most black donors phenotyped – but we think Rh variants are problematic
 - Only 30% of white donors phenotyped – patchy AND they are 97% of donors
 - Relying on black donors to meet the need of sickle patients is not realistic
- **Numbers of blood groups potentially to match:**
 - >200 blood groups
- **Blood ordering:**
 - done on a group not patient basis



- **Number of units to be matched:**
 - 10,000 units per month for people with sickle in England
- **Available interconnectivity:**
 - There is no meaningful connectivity between NHSBT and hospitals and often within hospitals
- **Selection of blood for transfusion at NHSBT:**
 - Performed manually
- **Stock maintenance and donations:**
 - Not precision managed to meet patient demand
 - A push rather than pull model



So we need three things:

- **Well typed patients** -> Sickle cell and thalassaemia blood group genotyping programme
- **Extended and appropriately typed donors** -> currently under discussion at NHSBT
- **An algorithm to match blood, embedded within NHSBT** -> Haem-Match

Haem-Match?

- To deliver **AI driven genomically matched blood to the patient beside** in order to:
 - **Reduce the risk of harm** caused by transfusion (antibody formation/alloimmunisation/transfusion reactions)
 - **To streamline the allocation of precisely genetically matched units** to patients with complicated transfusion needs
 - **Reduce waste and improve efficiency** in the collection and allocation of blood units.
- Patient cohorts
 - Sickle cell disorder (SCD)
 - Scope this work for other transfusion dependent anaemias such as Thalassaemia and Myelodysplastic Syndrome (MDS).





Blood Genomics Consortium

The Blood transfusion Genomics Consortium (BGC) is an international partnership between blood services, research institutions and industry leaders. Their aim is to improve the safety and efficiency of blood and platelet transfusion by introducing cutting-edge genomics technology into routine clinical practice. As the part of the BGC, the national blood services of Australia, Canada, England, Finland, New Zealand, the Netherlands, and South Africa together with the New York Blood Center work in partnership with UCLH academic hospitals in Boston and Cambridge, and Thermo Fisher Scientific to develop the DNA-based assays, software solutions, and infrastructure required to implement donor and patient genotyping at global scale. The work of the BGC has been crucial in developing the platform for the genetic blood grouping.

[Website](#)



The UCLH Biomedical Research Centre (BRC)

The UCLH Biomedical Research Centre (BRC) is a partnership between University College London Hospitals NHS Foundation Trust (UCLH) and UCL (University College London). The UCLH BRC was established in 2007 as one of five centres that were competitively awarded funding by the [National Institute for Health Research \(NIHR\)](#) to support world leading clinical translational research. In September 2018, the UCLH BRC was awarded £11.6M for 2017-2022 to enable continued growth in our experimental medicine and early translational research programmes. NIHR UCLH BRC will be funding staff and delivering much of the infrastructure to enable the large scale data collection and analysis needed to support the Haem-Match programme.

[Website](#)



Blood and Transplant

NHSBT Research and Development

NHSBT through its Research and Development arm and the organisation more widely has been providing some of the initial funds, support and expertise to develop the initial phases of the programme. In addition many of the team are salaried NHSBT employees and part of their work is to support the Haem-Match Programme.

[Website](#)



NIHR Artificial Intelligence in Health and Care

The Haem-Match consortium was successful in acquiring funding through a competitive application to the NIHR - AI systems for precision blood group matching. This will fund the salaries of staff that will develop the artificial intelligence programmes that will be needed for the precision blood matching, blood stock maintenance and donor recruitment.

[Website](#)



The National Institute for Health Research (NIHR) Blood and Transplant Research Unit (BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. The Unit is funded by the [NIHR](#) and is a partnership between the [University of Cambridge](#) and [NHS Blood and Transplant \(NHSBT\)](#). In collaboration with the [University of Oxford](#) and the [Wellcome Sanger Institute](#), The Public Patient Involvement and Engagement (PPI) group and the NIHR AI grant work are led through this BTRU.

[Website](#)




[Sanquin](#) is responsible for safe and efficient blood supply in the Netherlands on a not-for-profit basis. Sanquin also develops and produces pharmaceutical products, conducts high-quality scientific research, and develops and performs a multitude of diagnostic services. Researchers at Sanquin including Professor Ellen van de Schoot, Professor Barbara Veldhuisen and Mr Anton van Waert have led the way in the development of antigen typing and the development of AI systems for blood matching and we will be collaborating with them on this and other aspects of Haem-Match.

[Website](#)


Haem-Match Funding



Haem Match




Blood Antigen Genotyping



NIHR HIC TDA Database



Donor/Patient Demand Modelling




Informatics

WORK PACKAGE 1

WORK PACKAGE 2

WORK PACKAGE 3

WORK PACKAGE 4



Artificial Intelligence



Health Economics



PPIE



Clinical Studies

WORK PACKAGE 5


WORK PACKAGE 6

WORK PACKAGE 7

WORK PACKAGE 8

Work-Package 2 – NIHR HIC Transfusion Dependent Anaemias (TDA)

- Building the evidence base on which the algorithm will depend
- New theme within the NIHR Health Informatics Collaborative – Transfusion Dependent Anaemias
- Brings together transfusion and clinical data from hospitals and NHSBT to a TRE
- REC approved




Work Package 3: Donor and Patient modelling

- Multiple sources of information
 - PULSE
 - NIHR HIC
 - HEMATOS
 - INTERVAL/COMPARE/STRIDES
- Approvals through DPIA or ethics as appropriate




Work Package 4 - Informatics


- Part of the Genomics programme for NHSBT
- Searchable database for output of Axiom™ Total Blood Typing Solution designed




Work Package 5- Matching algorithm

- NIHR AI grant
- £1.23 m







Optimal Transport

Credit for the next few slides:

Dr Nick Gleadall, Dr Folarin Oyebolu, Dr Orod Razeghi

- Problem proposed by Monge in 1781
- What is the most efficient way to move mass between distributions
- Linear Program for doing this invented by Leonid Kantorovich in 1940s – **Rare Resource Allocation**




$$\min_{m, m\# \mu_s = \mu_t} \int c(x, m(x)) d\mu_s(x),$$



$$\begin{aligned} \gamma^* &= \arg \min_{\gamma \in \mathbb{R}_+^{m \times n}} \sum_{i,j} \gamma_{i,j} M_{i,j} \\ \text{s. t. } \gamma \mathbf{1} &= a; \gamma^T \mathbf{1} = b; \gamma \geq 0 \end{aligned}$$



Intuition

Manhattan Bakeries and Cafés



- People love Croissants (🥐) for breakfast
- **5 Cafes** in Manhattan sell the best 🥐 from **8 Bakeries**
- Each **Cafe** sells a different number of 🥐 :
82, 88, 92, 88, 91
- Each **Bakery** produces a different number of 🥐 :
31, 48, 82, 30, 40, 48, 89, 73

Intuition



OT in blood allocation



Stock Data (n=2000)

ID	ABO	D	C	E	c	e	K	S	s	Fya	Fyb	Jka	Jkb	Units Available
1	A	+	+	+	+	+	-	-	nan	-	nan	-	+	1
50	A	+	-	+	+	-	-	-	+	-	+	+	-	1
100	B	+	+	-	-	+	-	-	+	-	+	+	+	2
150	O	+	+	-	-	+	-	+	-	-	+	+	-	1
200	O	-	-	-	+	+	-	-	+	-	+	+	-	3

(truncated)

Recipient Data (n=10)

Recipient	ABO	D	C	E	c	e	K	S	s	Fya	Fyb	Jka	Jkb	#
1	B	+	-	-	+	+	-	-	+	+	-	-	+	4
2	A	+	+	+	+	+	+	+	-	+	+	+	-	4
3	A	-	-	-	+	+	-	-	+	+	-	+	+	7
4	O	+	+	-	-	+	-	-	+	+	+	-	+	3
5	A	+	+	-	+	+	-	+	+	+	+	+	-	4
6	O	+	-	+	+	-	-	-	+	+	+	+	+	8
7	AB	+	+	-	-	+	-	-	+	+	-	+	+	8
8	A	+	-	-	+	+	-	+	+	-	+	+	-	6
9	B	-	-	-	+	+	-	-	+	-	+	+	+	2
10	B	+	+	-	-	+	-	+	+	-	+	+	+	2



OT in blood allocation


There is an abstract distance between the blood of two people
- **Compatibility Distance**

In this example, a simple algorithm is applied to all pairwise combinations:

Incompatible (e.g. A -> B or + > -) = Inf


Compatible (e.g. O -> A or - > +) = 0.5

Match (e.g. A -> A, - > -, + > +) = 0



Early Simulations

- Used textbook antigen frequencies to simulate stock & Sickle Cell patient cohort data from UCLH to simulate demand
- Did series of 'on the day' and 6-week time horizon models
- Matching approach works well and significantly reduces expected immunisations over current 'reactive' matching policy



Simulation of matching for six weeks

1386 patients, 10 units each – ~14,000 units in total

	Limited	Extended
Expected number of alloimmunisations	7.92 ± 0.004	4.10 ± 0.007
Reduction from Limited	-	48%
Expected units short	3.73 ± 0.145	3.74 ± 0.152



Work Package 6: Health Economics

- NiHR AI Grant plus support from NHSBT
- Based at UCL
- Plotting the whole pathway of blood transfusion -> and comparing our current processes with proposed pathway
- Full health economic evaluation

Work Package 7: Patient Public Involvement and Engagement

- **Patient transfusion panel** established to advise on the project



Dr Rachel Kesse-Adu
panel chair


- **Staff transfusion panel** established, including **NHS laboratory staff**

Work Package 8: Feasibility/Pilot study

- Aims:
 - 1°:
 - To evaluate the ability of the Decision Support Algorithm (bloodMatcher) to allocate blood for SCD patients in a single SHU and single hospital
 - 2°:
 - To measure the impact of bloodMatcher on current hospital/NHSBT processes and blood stocks
 - To measure the degree of matching achieved vs standard process




Process: based on HLA matched plts



What antigens will we aim to match?

- Based on published evidence
- Algorithm will have to match as per current guidance
- In addition, if stock available and antigen negative, match for Fya, Fyb, S, Jka, Jkb







Feasibility study design

- NHSBT Colindale SHU -> One hospital (UCLH)
- 8 months
- Consented SCD patients, regular planned exchange transfusions
- Pilot – 2-3 patients, November 2024
- De-glitching, December 2024
- Rest of participants mid-January 2025 – mid-June
- Overall: 40 participants, max of 3 exchange transfusions each
- Approximately $40 \times 3 \times 10 = 1200$ units of blood

What next?

- Donor extended typing needs to ramp up
- Feasibility study completed and then funds for a larger multicentre study
- Work on other aspects of automation e.g. bloodstocker





Haem Match

Sara Trompeter
UCL, UCLH & NHS Blood and Transplant



Find out more:
www.haemmatch.org
www.bgc.io



<https://www.nhsbt.nhs.uk/what-we-do/clinical-and-research/blood-group-genotyping/>